Pfizer Discontinues Hemophilia Gene Therapy Beqvez

Pfizer stops commercialization of hemophilia gene therapy Beqvez
Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing soft demand from patients and their doctors. Beqvez is a one-time therapy that was approved in the U.
Pfizer discontinues hemophilia treatment Beqvez, emptying its gene therapy portfolio
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia B product Beqvez.
Pfizer stops selling hemophilia gene therapy, citing weak demand
Pfizer’s decision to halt further marketing of Beqvez is further sign of the sparse patient interest in gene therapies for the bleeding condition.
Pfizer says it will end global development of hemophilia gene therapy Beqvez
Pfizer said on Thursday it will end global development of its hemophilia gene therapy, Beqvez, citing soft demand from patients and their doctors. Beqvez was approved in the U.S. last year, for the treatment of adults with moderate to severe hemophilia B.
Pfizer Discontinues Hemophilia Gene Therapy Beqvez As Interest Wanes
According to multiple media reports on Thursday, Pfizer Inc. (NYSE:PFE) has terminated the global development and commercialization of its hemophilia B gene therapy, Beqvez. In April 2024, the FDA approved Beqvez for moderate to severe hemophilia B in adult patients who currently use factor IX prophylaxis therapy or have current or historical life-threatening hemorrhage,
Pfizer Axes Beqvez Worldwide, Pivoting Away From Gene Therapy for Hemophilia
The move comes weeks after Pfizer terminated its partnership with Sangamo Therapeutics for another hemophilia gene therapy.
Pfizer halts work on hemophilia gene therapy, Nikkei reports
Pfizer (PFE) will end global development and commercialization of Beqvez, a gene therapy for hemophilia, Nikkei learned Thursday, after the
Pfizer halts work on hemophilia gene therapy
NEW YORK/TOKYO -- Pfizer will end global development and commercialization of Beqvez, a gene therapy for hemophilia, Nikkei learned Thursday, after the drugmaker dropped its other similar treatment for the disorder in December.
Pfizer said to be discontinuing Roche-partnered hemophilia therapy Beqvez
Pfizer (NYSE:PFE) has decided to end R&D and marketing activities related to Beqvez, a one-time gene therapy the company has developed with Roche’s (OTCQX:RHHBY) (OTCQX:RHHBF) Spark Therapeutics for hemophilia B,
ENDPOINTS NEWS1d
Pfiz­er ends roll­out of Be­qvez, putting an­oth­er dent in he­mo­phil­ia gene ther­a­py field
Pfizer ends commercialization of Beqvez hemophilia B gene therapy. CEO Kim Phelan of Coalition for Hemophilia B expresses ...
Hemophilia Market Insights: Key Trends and Developments Across Different Types of Hemophilia | DelveInsight
The hemophilia market is expected to experience significant growth due to advancements in gene therapy, innovative treatments, and an increasing focus on personalized medicine. Rising awareness and ...
Pharm Exec12d
Mim8 Demonstrates Promising Results in Pediatric Patients with Hemophilia A
Data from the Phase III FRONTIER3 trial found that 98% of caregivers prefer Mim8 for hemophilia A over other treatments.
Alnylam: Waiting For Regulatory Updates In March
Alnylam awaits FDA decisions on Amvuttra & Fitusiran next month, poised to boost revenue, profitability, and share growth.
hemophilianewstoday1d
The hidden symptoms of hemophilia we rarely talk about
Columnist Jennifer Lynne stresses the significance of hidden symptoms in the lives of those with bleeding disorders.